ReviewFrontiers in pain research (Lausanne, Switzerland)2026
Liposomal bupivacaine in lower extremity arthroplasty: a comprehensive review.
Review in Frontiers in pain research (Lausanne, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative pain management following lower extremity joint arthroplasty (TKA, THA, and ankle procedures) remains a significant clinical challenge, with approximately two-thirds of patients reporting moderate-to-severe pain within the first 24 h. Conventional local anesthetics, which have a short duration of action (6-8 h), frequently fail to provide prolonged analgesia, leading to opioid dependence and its associated risks. Liposomal bupivacaine (LB), a sustained-release formulation based on DepoFoam™ technology, provides analgesia for up to 72 h, thereby addressing this clinical gap. Methods: This systematic review assesses the efficacy and safety of LB through an analysis of nine randomized controlled trials (RCTs; Results: LB demonstrated superior outcomes, including a 35%-50% reduction in 24-hour opioid requirements (pooled relative risk [RR] = 0.62; 95% CI: 0.32-0.89; Conclusion: LB provides clinically significant opioid-sparing effects and enhances postoperative recovery, though its cost-benefit profile requires careful assessment. Future studies should focus on formulation optimization, expanded clinical applications, and improved pharmacoeconomic approaches to establish its definitive role in enhanced recovery after surgery (ERAS) protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.